Isoniazid, Pyrazinamide and Rifampicin Content Variation in Split Fixed-Dose Combination Tablets

Setting In most developing countries, paediatric tuberculosis is treated with split tablets leading to potential inaccuracy in the dose delivery and drug exposure. There is no data on the quality of first-line drugs content in split fixed-dose combination tablets. Objective To determine Isoniazid, Pyrazinamide and Rifampicin content uniformity in split FDC tablets used in the treatment of childhood tuberculosis. Design Drug contents of 15 whole tablets, 30 half tablets and 36 third tablets were analysed by high performance liquid chromatography. The content uniformity was assessed by comparing drug content measured in split portions with their expected amounts and the quality of split portions was assessed applying qualitative specifications for whole tablets. Results All whole tablets measurements fell into the USP proxy for the three drugs. But a significant number of half and third portions was found outside the tolerated variation range and the split formulation failed the requirements for content uniformity. To correct for the inaccuracy of splitting the tablets into equal portions, a weight-adjustment strategy was used but this did not improve the findings. Conclusion In split tablets the content of the three drugs is non-uniform and exceeded the USP recommendations. There is an absolute need to make child-friendly formulations available for the treatment of childhood tuberculosis.

[1]  D. Gibb,et al.  Young HIV-Infected Children and Their Adult Caregivers Prefer Tablets to Syrup Antiretroviral Medications in Africa , 2012, PloS one.

[2]  A. Diacon,et al.  The pharmacokinetics and pharmacodynamics of rifampicin in adults and children in relation to the dosage recommended for children. , 2011, Tuberculosis.

[3]  S. Graham Mini-symposium : Childhood TB in 2010 Treatment of paediatric TB : revised WHO guidelines , 2010 .

[4]  S. Swaminathan,et al.  Pediatric tuberculosis: global overview and challenges. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  U. Wahn,et al.  Rifampicin serum levels in childhood tuberculosis. , 2009, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[6]  K. Karlage,et al.  Analysis of drug content and weight uniformity for half-tablets of 6 commonly split medications. , 2009, Journal of managed care pharmacy : JMCP.

[7]  P. Donald The assessment of new anti-tuberculosis drugs for a paediatric indication. , 2007, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[8]  S. Ward,et al.  Low Levels of Pyrazinamide and Ethambutol in Children with Tuberculosis and Impact of Age, Nutritional Status, and Human Immunodeficiency Virus Infection , 2006, Antimicrobial Agents and Chemotherapy.

[9]  R. Gie,et al.  Management of the child with cough or difficult breathing. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[10]  P. V. van Helden,et al.  Isoniazid pharmacokinetics in children treated for respiratory tuberculosis , 2005, Archives of Disease in Childhood.

[11]  R. Shankar,et al.  A critical review of the probable reasons for the poor variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem. , 2001, International journal of pharmaceutics.

[12]  P. B. Fourie,et al.  Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[13]  C. T. Viswanathan,et al.  Pharmacokinetics of rifampin in children. II. Oral bioavailability. , 1986, Therapeutic drug monitoring.